by Barry101 | Nov 4, 2024 | Press Release
Warns Shareholders that Activist Group’s Self-Interested Agenda Could Disrupt AIM’s Momentum and Destroy Chances for Near-Term Value Creation Expresses Excitement About Encouraging Progress of Clinical Trials for Ampligen in High-Value Indications...
by Barry101 | Oct 9, 2024 | Press Release
Live webcast fireside chat on Wednesday, October 16th at 12:30 PM ETOCALA, Fla., Oct. 09, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that Tom Equels, Chief Executive Officer of AIM, will...
by Barry101 | Oct 3, 2024 | Press Release
OCALA, Fla., Oct. 03, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. patent No. 12,102,649, covering both compositions...
by Barry101 | Sep 30, 2024 | Press Release
OCALA, Fla., Sept. 30, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 4,653,036 shares of...
by Barry101 | Sep 27, 2024 | Press Release
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, October 2nd at 4:00 PM ETOCALA, Fla., Sept. 27, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that...
by Barry101 | Sep 19, 2024 | Press Release
Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort Combination of Ampligen and Imfinzi continues to be generally well-tolerated with no severe adverse events or dose-limiting toxicities OCALA, Fla., Sept. 19,...
